|
Dedication |
6 |
|
|
Foreword |
8 |
|
|
Preface |
10 |
|
|
Organization and Content |
10 |
|
|
Features |
10 |
|
|
Series Editor Page |
12 |
|
|
About Series Editor |
20 |
|
|
About Volume Editors |
24 |
|
|
Acknowledgements |
28 |
|
|
Contents |
30 |
|
|
Contributors |
34 |
|
|
Part IFoundations for Clinical Practice and Overview |
37 |
|
|
Chapter 1: Kidney Function in Health and Disease |
38 |
|
|
Introduction |
38 |
|
|
Clinical Evaluation of Kidney Function |
41 |
|
|
Kidney Function in Disease States |
42 |
|
|
Summary |
45 |
|
|
References |
45 |
|
|
Chapter 2: Global Perspective of Kidney Disease |
46 |
|
|
Introduction |
46 |
|
|
Epidemiology of CKD and ESRD |
47 |
|
|
Provision of Renal Replacement Therapy |
48 |
|
|
Modality Use |
51 |
|
|
Nutrition as a Risk Factor and Key Intervention |
54 |
|
|
Summary |
56 |
|
|
References |
56 |
|
|
Chapter 3: Dietary Assessment in Kidney Disease |
59 |
|
|
Introduction |
60 |
|
|
Purpose and Utility of Dietary Intake Assessment |
60 |
|
|
Methodology of Dietary Intake Assessment |
62 |
|
|
24-h Recall |
63 |
|
|
Automated Multiple-Pass Method |
63 |
|
|
The Automated Self-Administered 24-h Recall |
63 |
|
|
Food Frequency Questionnaire |
66 |
|
|
Block FFQ |
66 |
|
|
Willett FFQ |
66 |
|
|
Diet History Questionnaire |
67 |
|
|
FFQ Data Analysis |
67 |
|
|
Diet Record or Diary |
67 |
|
|
Application of Dietary Intake Assessment to Dietary Guidelines |
68 |
|
|
Dietary Intake Assessment of Individuals |
68 |
|
|
Dietary Intake Assessment of Groups |
68 |
|
|
Evidence |
70 |
|
|
Assessment of the 24-h Recall, the AMPM |
70 |
|
|
Assessment of the FFQ |
71 |
|
|
Use of Biomarkers in Assessing Dietary Intake |
71 |
|
|
Doubly Labeled Water and Urine Urea Nitrogen for Dietary Energy and Protein Intake Assessment |
72 |
|
|
Plasma Ascorbic Acid, Carotenoids, and Vitamin A Levels for Assessing Dietary Intake |
72 |
|
|
Association of Serum Uric Acid Levels and Urinary Isoflavones with Dietary Intake |
72 |
|
|
Applications to Kidney Disease Settings |
73 |
|
|
Acute Kidney Injury |
73 |
|
|
Chronic Kidney Disease |
74 |
|
|
Nondialysis CKD |
74 |
|
|
Small Studies |
74 |
|
|
Large Cohort and Cross-Sectional Studies |
75 |
|
|
Dialysis |
76 |
|
|
The FFQ in Dialysis |
76 |
|
|
Diet Records in Dialysis |
76 |
|
|
Transplantation |
77 |
|
|
The FFQ in Kidney Transplantation |
77 |
|
|
Diet Records in Kidney Transplantation |
77 |
|
|
Recommendations for Kidney Disease |
77 |
|
|
References |
78 |
|
|
Chapter 4: Anthropometric Assessment in Kidney Disease |
83 |
|
|
Weight and Height Measurements |
86 |
|
|
Skinfold and Circumference Measurements |
87 |
|
|
Somatogram |
88 |
|
|
Frame Size |
88 |
|
|
Somatotyping |
88 |
|
|
Reference Data |
88 |
|
|
Summary |
89 |
|
|
References |
89 |
|
|
Chapter 5: Biochemical Nutritional Assessment in Chronic Kidney Disease |
91 |
|
|
Introduction |
91 |
|
|
Biochemical Assessment of Nutritional Status |
92 |
|
|
Protein–Energy Nutritional Status |
93 |
|
|
Serum Albumin |
94 |
|
|
Serum Prealbumin |
95 |
|
|
Serum Creatinine and Creatinine Index |
95 |
|
|
Serum Total Cholesterol |
96 |
|
|
Serum Transferrin |
96 |
|
|
Markers of Inflammation |
96 |
|
|
C-Reactive Protein and Proinflammatory Cytokines |
97 |
|
|
Nutritional Adequacy and Management |
98 |
|
|
Protein Intake |
98 |
|
|
Metabolic Acidosis |
98 |
|
|
Summary of Biochemical Assessment |
99 |
|
|
References |
100 |
|
|
Chapter 6: Nutrition Physical Assessment in Chronic Kidney Disease (CKD) |
103 |
|
|
Rationale for Performing a Nutrition Physical Examination |
103 |
|
|
Nutrition-Focused Physical Examination |
104 |
|
|
Approach to Tissue-Specific Physical Assessment |
105 |
|
|
Physical Examination |
105 |
|
|
Observing Oral Tissues |
105 |
|
|
Scalp, Hair, and Skin Findings |
106 |
|
|
Examination of the Eyes |
106 |
|
|
Examination of the Nails |
106 |
|
|
Physical Findings and Functional Deficits in Niacin, B 6, and Zinc Imbalance |
107 |
|
|
Niacin |
107 |
|
|
Vitamin B 6 |
109 |
|
|
Vitamin B 6 Deficiency |
109 |
|
|
Vitamin B 6 Toxicity |
111 |
|
|
Zinc |
111 |
|
|
Zinc Deficiency |
111 |
|
|
Zinc Toxicity |
115 |
|
|
Placing Physical Findings Within the Clinical Context of the Patient |
115 |
|
|
Summary of the Nutrition Physical Assessment |
115 |
|
|
References |
118 |
|
|
Part IIChronic Kidney Disease Among Adults |
124 |
|
|
Chapter 7: Hypertension |
125 |
|
|
Introduction |
125 |
|
|
Nutrients and Blood Pressure |
126 |
|
|
Sodium |
126 |
|
|
Potassium |
126 |
|
|
Calcium and Dairy Foods |
127 |
|
|
Magnesium |
127 |
|
|
Protein |
128 |
|
|
Fatty Acids |
128 |
|
|
Vitamin C |
128 |
|
|
The DASH Diet |
129 |
|
|
Dietary Recommendations for Hypertension |
130 |
|
|
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Recommendations |
130 |
|
|
KDOQI Guidelines |
130 |
|
|
Summary |
131 |
|
|
References |
131 |
|
|
Chapter 8: Diabetes Mellitus and Chronic Kidney Disease (Stages 1–5) |
134 |
|
|
Introduction |
134 |
|
|
Pathophysiology of Diabetic Nephropathy |
135 |
|
|
Goals of Therapy |
138 |
|
|
Microvascular Complication Prevention |
138 |
|
|
Macrovascular Complication Prevention |
138 |
|
|
Hypertension Management |
140 |
|
|
CVD Risk Management |
140 |
|
|
Medical Nutrition Therapy |
141 |
|
|
Energy Needs and Weight Management |
141 |
|
|
Dietary Strategies for Carbohydrate (CHO) Management |
143 |
|
|
Glycemic Index |
143 |
|
|
Fiber |
145 |
|
|
Protein Guidelines for Diabetes and CKD |
145 |
|
|
Dietary Fat Recommendations |
147 |
|
|
Special Considerations |
147 |
|
|
Hypoglycemia/Uremia |
147 |
|
|
Hyperglycemia and Potassium |
148 |
|
|
Dietary Changes |
148 |
|
|
Alcohol |
148 |
|
|
Nutritive and Non-nutritive Sweeteners |
148 |
|
|
Vitamin D |
149 |
|
|
MNT Summary |
149 |
|
|
Medicare Reimbursement for MNT |
150 |
|
|
Pharmacological Management of Diabetes Within CKD |
150 |
|
|
Oral Anti-hyperglycemic Agents |
150 |
|
|
Medications Targeting Insulin Resistance |
151 |
|
|
Metformin |
151 |
|
|
Thiazolidinediones |
151 |
|
|
Medications Targeting Insulin Secretion |
153 |
|
|
Sulphonylureas |
153 |
|
|
Meglitinides |
153 |
|
|
Incretin-Based Therapies |
154 |
|
|
Medications Targeting Postprandial Glucose |
154 |
|
|
Insulin |
154 |
|
|
Other Medications |
155 |
|
|
Self-Monitoring of Blood Glucose |
155 |
|
|
ESRD and DM |
155 |
|
|
Hemodialysis |
156 |
|
|
Peritoneal Dialysis |
156 |
|
|
Monitoring Glycemic Control |
157 |
|
|
Medical Nutrition Therapy on Dialysis |
158 |
|
|
Malnutrition |
158 |
|
|
Fluid Control |
159 |
|
|
Gastroparesis |
159 |
|
|
Summary |
159 |
|
|
Case Study |
160 |
|
|
Questions |
160 |
|
|
References |
161 |
|
|
Chapter 9: Dyslipidemias |
168 |
|
|
Introduction |
168 |
|
|
Pathophysiology |
169 |
|
|
Existing Clinical Practice Guidelines and Peer-Reviewed Recommendations |
169 |
|
|
Assessment |
170 |
|
|
Biochemical |
170 |
|
|
Physical |
170 |
|
|
Nutritional |
171 |
|
|
Intervention |
171 |
|
|
Lifestyle |
171 |
|
|
Dietary |
172 |
|
|
Determination of Nutrition Prescription |
172 |
|
|
Amount and Type of Dietary Fat |
173 |
|
|
Incorporation of Type of Carbohydrate, Dietary Fiber, and Plant Sterols |
174 |
|
|
Pharmacological |
175 |
|
|
Summary |
176 |
|
|
References |
176 |
|
|
Chapter 10: Implications and Management of Obesity in Kidney Disease |
178 |
|
|
Introduction |
178 |
|
|
Case Scenario |
179 |
|
|
Defining Obesity |
179 |
|
|
Measuring Kidney Parameters in Obese Individuals |
180 |
|
|
Epidemiology and Trends in Obesity |
181 |
|
|
Obesity and Clinical Risk |
182 |
|
|
Chronic Kidney Disease Stages 1–4 |
182 |
|
|
End-Stage Renal Disease (Stage 5) |
183 |
|
|
Kidney Transplant Recipients |
185 |
|
|
Influence of Obesity on Kidney Function, Structure, and Health |
185 |
|
|
Kidney Mass |
186 |
|
|
Renal Hemodynamics |
186 |
|
|
Proteinuria |
186 |
|
|
Histologic Changes |
186 |
|
|
Molecular Findings |
187 |
|
|
Obesity-Related Glomerulopathy and Glomerulosclerosis |
187 |
|
|
Animal Models of Weight Gain and Loss |
188 |
|
|
Pathophysiology of Obesity-Related Kidney Disease |
189 |
|
|
Dietary Protein |
189 |
|
|
Podocyte Depletion |
189 |
|
|
Intraglomerular Hemodynamics |
190 |
|
|
Renin-Angiotensin-Aldosterone Axis |
190 |
|
|
Sympathetic Activation |
190 |
|
|
Obstructive Sleep Apnea |
190 |
|
|
Insulin Resistance and the Metabolic Syndrome |
190 |
|
|
Lipotoxicity |
191 |
|
|
Fatty Kidney |
191 |
|
|
Adipocyte Secretory Products |
191 |
|
|
Prevalence of Obesity-Related Kidney Disease |
191 |
|
|
Weight-Loss Strategies and Benefits |
192 |
|
|
Chronic Kidney Disease Stages 1–4 |
192 |
|
|
End-Stage Renal Disease (Stage 5) |
193 |
|
|
Kidney Transplant Recipients |
193 |
|
|
References |
193 |
|
|
Part IIIKidney Disease in Adults Treated by Renal Replacement Therapies |
201 |
|
|
Chapter 11: Dialysis |
202 |
|
|
Introduction |
202 |
|
|
Factors Influencing Nutritional Status |
203 |
|
|
Nutrient Recommendations in Dialysis |
205 |
|
|
Energy |
205 |
|
|
Hemodialysis |
205 |
|
|
Peritoneal Dialysis |
205 |
|
|
Nocturnal Hemodialysis/Short Daily Hemodialysis |
206 |
|
|
Protein |
208 |
|
|
Hemodialysis |
208 |
|
|
Peritoneal Dialysis |
208 |
|
|
PNA: Hemodialysis and Peritoneal Dialysis |
208 |
|
|
Nocturnal Hemodialysis/Short Daily Hemodialysis |
209 |
|
|
Nutrition Support |
209 |
|
|
Sodium and Fluid |
209 |
|
|
Hemodialysis |
209 |
|
|
Peritoneal Dialysis |
210 |
|
|
Nocturnal Hemodialysis/Short Daily Hemodialysis |
210 |
|
|
Potassium |
211 |
|
|
Hemodialysis |
211 |
|
|
Peritoneal Dialysis |
211 |
|
|
Nocturnal Hemodialysis/Short Daily Hemodialysis |
212 |
|
|
Calcium/Phosphorus/Vitamin D |
212 |
|
|
Hemodialysis and Peritoneal Dialysis |
212 |
|
|
Nocturnal Hemodialysis/Short Daily Hemodialysis |
213 |
|
|
Lipids |
214 |
|
|
Hemodialysis |
214 |
|
|
Peritoneal Dialysis |
214 |
|
|
Nocturnal Hemodialysis/Short Daily Dialysis |
214 |
|
|
Vitamins, Minerals, and Trace Elements |
215 |
|
|
Water-Soluble Vitamins |
215 |
|
|
Fat-Soluble Vitamins |
216 |
|
|
Minerals and Trace Elements |
217 |
|
|
Summary |
218 |
|
|
Case Study |
218 |
|
|
Case Questions and Answers |
219 |
|
|
References |
220 |
|
|
Chapter 12: Transplantation |
225 |
|
|
Introduction |
225 |
|
|
The Pre-transplant Phase |
226 |
|
|
The Acute Post-transplant Period |
227 |
|
|
Nutritional Requirements |
227 |
|
|
Protein |
227 |
|
|
Energy |
229 |
|
|
Carbohydrate |
229 |
|
|
Fat |
229 |
|
|
Sodium |
229 |
|
|
Potassium |
229 |
|
|
Vitamins, Minerals, and Trace Elements |
230 |
|
|
Herbals |
230 |
|
|
Common Problems Post-transplant in the Acute Care Setting |
230 |
|
|
Inadequate Intake |
230 |
|
|
Hyperglycemia |
231 |
|
|
Gastrointestinal Issues |
231 |
|
|
Mineral and Bone Disorders |
231 |
|
|
Hyperkalemia |
232 |
|
|
The Chronic Post-transplant Phase |
232 |
|
|
Nutritional Requirements |
232 |
|
|
Calcium and Phosphorus |
233 |
|
|
Vitamins and Other Minerals |
233 |
|
|
Pharmacology Update |
233 |
|
|
Cyclosporine A or CsA (Sandimmune/Neoral) |
233 |
|
|
Tacrolimus (Prograf/FK506) |
235 |
|
|
Mycophenolate Mofetil or MMF (CellCept/RS-61443) |
236 |
|
|
Sirolimus (Rapamycin/Rapamune) |
236 |
|
|
Azathioprine (Imuran) |
236 |
|
|
Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Solu-Medrol, Solu-Cortef) |
236 |
|
|
Other Agents |
237 |
|
|
Long-Term Care Challenges |
237 |
|
|
Cardiovascular Disease |
237 |
|
|
Obesity |
238 |
|
|
New-Onset Diabetes After Transplantation (NODAT) |
239 |
|
|
Hypertension |
239 |
|
|
Mineral and Bone Disorder |
239 |
|
|
General Considerations |
239 |
|
|
Interactions |
239 |
|
|
Food Safety |
240 |
|
|
Summary |
240 |
|
|
Case Study |
240 |
|
|
Case Study Questions |
241 |
|
|
References |
243 |
|
|
Chapter 13: Protein-Energy Wasting |
246 |
|
|
Introduction |
246 |
|
|
Protein-Energy Wasting (PEW): Definition and Etiology |
247 |
|
|
Assessment of Protein-Energy Wasting |
249 |
|
|
Inflammation and Kidney Disease Wasting |
251 |
|
|
Consequences of PEW |
251 |
|
|
Refractory Anemia |
251 |
|
|
Atherosclerotic Cardiovascular Disease |
252 |
|
|
Reverse Epidemiology |
253 |
|
|
Management of PEW |
253 |
|
|
Summary |
254 |
|
|
References |
255 |
|
|
Chapter 14: Acute Kidney Injury |
258 |
|
|
Function of the Kidneys |
258 |
|
|
Acute Kidney Injury |
259 |
|
|
Renal Replacement Therapy |
260 |
|
|
Nutrition Management of the AKI Patient |
260 |
|
|
Nutrition Assessment |
260 |
|
|
Oral Intake and Supplements |
261 |
|
|
Specialized Nutrition Support |
262 |
|
|
Tube Feeding Formulas |
263 |
|
|
Tube Feeding Management |
263 |
|
|
Guidelines for Administration |
264 |
|
|
Parenteral Nutrition Support |
265 |
|
|
Use of Parenteral Nutrition (PN) |
265 |
|
|
Intradialytic Parenteral Nutrition Support |
265 |
|
|
Nutrient Substrates |
266 |
|
|
Protein |
266 |
|
|
Carbohydrate |
266 |
|
|
Fat |
266 |
|
|
Parenteral Additives |
267 |
|
|
Fluid and Electrolytes |
267 |
|
|
Vitamins and Trace Minerals |
267 |
|
|
Initiation and Monitoring of Parenteral Nutrition Support |
268 |
|
|
Discontinuing Parenteral Nutrition |
268 |
|
|
Monitoring Clinical and Laboratory Parameters |
268 |
|
|
Nutritional Requirements in AKI |
268 |
|
|
Energy Requirements |
269 |
|
|
Protein Requirements |
269 |
|
|
Fat Requirements |
270 |
|
|
Vitamins and Trace Elements |
270 |
|
|
Fluid, Electrolytes, and Mineral Needs |
271 |
|
|
Summary |
271 |
|
|
References |
271 |
|
|
Chapter 15: Bone and Mineral Disorders |
274 |
|
|
Introduction |
274 |
|
|
Pathogenesis of Bone and Mineral Abnormalities in CKD |
277 |
|
|
Bone Manifestations |
279 |
|
|
Bone Biopsy |
281 |
|
|
Radiography, Pulse Pressure, and Electron Beam Computed Tomography |
281 |
|
|
Bone Mineral Density |
282 |
|
|
Biochemical Markers of Bone and Mineral Metabolism in CKD |
282 |
|
|
Treatment of CKD-MBD |
284 |
|
|
Dietary Modification |
285 |
|
|
Outline Placeholder |
287 |
|
|
Nutritional Vitamin D |
289 |
|
|
Calcimimetics |
290 |
|
|
Alternative Dialysis Therapies |
291 |
|
|
Patient Education |
291 |
|
|
Parathyroidectomy |
291 |
|
|
Treatment Options for Adynamic Bone |
291 |
|
|
Summary |
292 |
|
|
Case Presentation |
292 |
|
|
References |
293 |
|
|
Chapter 16: Physical Activity and Exercise |
297 |
|
|
Introduction |
297 |
|
|
Physical Activity, Exercise, and Their Classification |
298 |
|
|
Benefits of Exercise in the General Population |
298 |
|
|
Potential Benefits of Increased Physical Activity Among Patients with CKD |
299 |
|
|
Risks of Physical Activity |
304 |
|
|
Approach to Prescribing and Promoting Physical Activity in the CKD Population |
305 |
|
|
Case Study |
308 |
|
|
Physical Function Evaluation (Fig. 16.4) [ 1 ] |
308 |
|
|
Recommended Activity |
310 |
|
|
Follow-Up Evaluation (6 Months) |
310 |
|
|
Physical Function Testing |
310 |
|
|
References |
311 |
|
|
Part IVNutrition in Chronic Kidney Disease Among Special Needs Populations |
314 |
|
|
Chapter 17: Pregnancy |
315 |
|
|
Background |
315 |
|
|
Confirmation of Pregnancy |
316 |
|
|
Dialysis Regimen |
316 |
|
|
Energy and Protein Needs |
317 |
|
|
Vitamins and Minerals |
318 |
|
|
Weight Gain and Serum Albumin |
318 |
|
|
Medications |
319 |
|
|
Breastfeeding |
319 |
|
|
Summary |
319 |
|
|
Case Study |
320 |
|
|
Questions |
321 |
|
|
References |
321 |
|
|
Chapter 18: Infancy, Childhood, and Adolescence |
323 |
|
|
Introduction |
324 |
|
|
Etiology of CKD* |
324 |
|
|
Treatment Modalities* |
324 |
|
|
Linear Growth |
325 |
|
|
Adequacy of Weight Gain and Nutritional Intake |
325 |
|
|
Assessment |
327 |
|
|
Nutrient Requirements |
330 |
|
|
Energy |
331 |
|
|
Protein |
332 |
|
|
Carbohydrate, Fats, and Lipid Management |
333 |
|
|
Vitamins and Minerals |
334 |
|
|
Sodium |
336 |
|
|
Potassium |
337 |
|
|
Phosphorus and Calcium |
338 |
|
|
Fluid |
340 |
|
|
Age-Related Intervention and Monitoring |
340 |
|
|
Infants and Toddlers (Ages 0–3) |
340 |
|
|
Children (Ages 4–12) |
342 |
|
|
Adolescents* (Ages 13 and Older) |
343 |
|
|
Enteral Nutrition |
343 |
|
|
Oral Supplementation |
343 |
|
|
Tube Feeding |
344 |
|
|
Parenteral Nutrition |
346 |
|
|
Intradialytic Parenteral Nutrition |
346 |
|
|
Intraperitoneal Amino Acid Dialysis* |
347 |
|
|
Transplant |
347 |
|
|
Transition |
349 |
|
|
Summary* |
350 |
|
|
Case Study* |
350 |
|
|
Questions |
350 |
|
|
References |
351 |
|
|
Chapter 19: The Aging Adult |
357 |
|
|
Introduction |
357 |
|
|
Profile of Older American |
358 |
|
|
Marital Status and Living Arrangements |
358 |
|
|
Economic Status |
358 |
|
|
Normal Physiological Changes |
358 |
|
|
Sensory |
359 |
|
|
Skin |
359 |
|
|
Respiratory |
359 |
|
|
Cardiovascular |
359 |
|
|
Gastrointestinal |
359 |
|
|
Musculoskeletal |
360 |
|
|
The Kidneys |
360 |
|
|
Aging and Kidney Function |
360 |
|
|
Aging and CKD Risk Factors |
361 |
|
|
Heightened Risks in Older Adults with CKD |
361 |
|
|
Hypotension |
362 |
|
|
Increased Falls Risk |
362 |
|
|
Vascular Dementia |
362 |
|
|
Protein Energy Wasting |
362 |
|
|
Anemia Management |
363 |
|
|
Bone Disease Management |
363 |
|
|
Geriatric Focus |
363 |
|
|
Barriers to Care |
363 |
|
|
Geriatric Assessment |
364 |
|
|
Summary |
365 |
|
|
Case Study |
366 |
|
|
Questions |
366 |
|
|
References |
367 |
|
|
Chapter 20: Nephrotic Syndrome |
369 |
|
|
Definition of Nephrotic Syndrome |
369 |
|
|
Causes of Nephrotic Syndrome |
370 |
|
|
Complications of Nephrotic Syndrome |
371 |
|
|
Sodium Retention (Edema) |
371 |
|
|
Hypercoagulability (Thrombophilia) |
372 |
|
|
Hyperlipidemia |
372 |
|
|
Progressive Renal Injury |
372 |
|
|
Infection |
373 |
|
|
Nutritional Depletion |
373 |
|
|
Treatment of Nephrotic Syndrome |
373 |
|
|
Specific Treatment |
374 |
|
|
Nonspecific Treatment |
374 |
|
|
Pharmacologic Management |
374 |
|
|
Nutritional Management |
375 |
|
|
Summary |
375 |
|
|
References |
376 |
|
|
Chapter 21: Nephrolithiasis |
378 |
|
|
Introduction |
378 |
|
|
Symptoms and Diagnosis [ 9 ] |
379 |
|
|
Evaluation of New Stones |
379 |
|
|
Evaluation of Recurrent Stones and Follow-up |
380 |
|
|
Stone Formation |
380 |
|
|
Supersaturation (SS) and Stone Formation |
380 |
|
|
Interpretation of Biochemical and Urine Tests |
381 |
|
|
The 24-h Urine Collection |
381 |
|
|
Risk Factors for Kidney Stone |
383 |
|
|
Urine Volume |
384 |
|
|
Hypercalciuria |
384 |
|
|
Hyperoxaluria |
385 |
|
|
Hypocitraturia |
385 |
|
|
pH |
386 |
|
|
Uric Acid |
386 |
|
|
Dietary Factors |
387 |
|
|
Sodium |
387 |
|
|
Potassium |
387 |
|
|
Protein |
388 |
|
|
Calcium |
388 |
|
|
Magnesium |
388 |
|
|
Vitamin C |
389 |
|
|
Other Dietary Factors |
389 |
|
|
Nutrition Assessment and Recommendation |
389 |
|
|
Common Mistakes |
389 |
|
|
Practical Rule of Thumb |
389 |
|
|
General Recommendations |
391 |
|
|
Summary |
393 |
|
|
Case Studies |
393 |
|
|
Case #1 (Table 21.10) |
393 |
|
|
Case #2 (Table 21.11) |
394 |
|
|
References |
395 |
|
|
Part VAdditional Nutritional Considerations in Kidney Disease |
397 |
|
|
Chapter 22: Public Policy and Renal Nutrition Practice: Past, Present, and Future |
398 |
|
|
Public Policy and Renal Nutrition Practice: Past, Present and Future |
398 |
|
|
The Role of Federal and State Governments |
399 |
|
|
Direct Payment to Nutrition and Dietetics Practitioners |
399 |
|
|
The MNT Benefit |
400 |
|
|
What You Can Do to Promote Patient Access to Nutrition Care Provided by RD/Ns |
401 |
|
|
References |
401 |
|
|
Chapter 23: Dietary Supplements |
402 |
|
|
Introduction |
402 |
|
|
Dietary Supplements |
403 |
|
|
Box 23.1 Definition of Dietary Supplement [ 3 ] |
403 |
|
|
Efficacy and Safety of CAM Therapies |
403 |
|
|
Box 23.2 Deciding For or Against the Use of Dietary Supplements |
404 |
|
|
Box 23.3 |
404 |
|
|
Dietary Supplements and Kidney Disease |
404 |
|
|
Dietary Supplements with Potential Protective Effects |
405 |
|
|
Dietary Supplements to Avoid in Kidney Disease |
405 |
|
|
Dietary Supplements and Kidney Dysfunction |
406 |
|
|
Considerations for Healthcare Providers |
406 |
|
|
Summary |
407 |
|
|
Resources |
407 |
|
|
References |
408 |
|
|
Chapter 24: Vitamin and Trace Element Needs in Chronic Kidney Disease |
409 |
|
|
Introduction |
409 |
|
|
Vitamin B1: Thiamin |
410 |
|
|
Vitamin B2: Riboflavin |
410 |
|
|
Niacin: Vitamin B3 |
411 |
|
|
Vitamin B6: Pyridoxine |
412 |
|
|
Folic Acid |
412 |
|
|
Cyanocobalamin: B12 |
413 |
|
|
Homocysteine |
413 |
|
|
Pantothenic Acid |
414 |
|
|
Vitamin C |
414 |
|
|
Fat-Soluble Vitamins |
415 |
|
|
Vitamin A |
415 |
|
|
Vitamin E |
416 |
|
|
Vitamin K |
417 |
|
|
Minerals and Trace Elements |
418 |
|
|
Copper |
418 |
|
|
Molybdenum |
418 |
|
|
Magnesium |
419 |
|
|
Manganese |
419 |
|
|
Selenium |
419 |
|
|
Zinc |
420 |
|
|
Summary |
420 |
|
|
References |
421 |
|
|
Chapter 25: Issues Affecting Dietary Adherence |
425 |
|
|
Introduction |
425 |
|
|
Definitions |
425 |
|
|
Dietary Adherence |
426 |
|
|
Factors Affecting Dietary Adherence |
426 |
|
|
Social and Economic Factors |
426 |
|
|
Health-Care Team and System-Related Factors |
427 |
|
|
Condition-Related Factors |
428 |
|
|
Therapy-Related Factors |
428 |
|
|
Patient-Related Factors |
428 |
|
|
Behavior Change Models |
428 |
|
|
Stages of Change |
429 |
|
|
Strategies for Achieving Dietary Adherence |
429 |
|
|
Summary |
431 |
|
|
References |
431 |
|
|
Chapter 26: Counseling Approaches |
432 |
|
|
Introduction |
432 |
|
|
The Transtheoretical Model |
433 |
|
|
Inquiries and Responding to Patients |
434 |
|
|
Closed-Ended Questions |
434 |
|
|
Leading Questions |
435 |
|
|
Open-Ended Questions |
435 |
|
|
Respond Using Reflective Listening |
436 |
|
|
Social Learning Theory and Self-Efficacy |
437 |
|
|
Behavior Modification and Cognitive Behavioral Therapy |
437 |
|
|
Cognitions |
438 |
|
|
Cognitive Distortions |
438 |
|
|
Cognitive Restructuring |
439 |
|
|
Goal Setting |
439 |
|
|
Motivational Interviewing |
440 |
|
|
Special Considerations for Patients Receiving Hemodialysis |
441 |
|
|
Future Directions |
442 |
|
|
Summary |
442 |
|
|
Case Study |
442 |
|
|
Questions for Case Study |
443 |
|
|
Answers to Case Study |
443 |
|
|
References |
444 |
|
|
Chapter 27: Outcomes Research |
446 |
|
|
Introduction and Overview |
446 |
|
|
Challenges for Nutrition |
447 |
|
|
Outcomes Research Defined |
448 |
|
|
Types of Outcomes |
449 |
|
|
Evidence-Based Practice Guidelines |
450 |
|
|
Practice Guidelines and Patient Care |
451 |
|
|
Dialysis Outcomes and Practice Patterns Study |
451 |
|
|
Summary |
452 |
|
|
References |
452 |
|
|
Chapter 28: Suggested Resources for the Practitioner |
455 |
|
|
Introduction |
455 |
|
|
Evidence-Based Practice Guidelines |
455 |
|
|
NKF KDOQI Practice Guideline Statements |
456 |
|
|
Academy of Nutrition and Dietetics Chronic Kidney Disease (Non-dialysis) Medical Nutrition Therapy Protocol |
465 |
|
|
Diet-Related Resources and Food Lists |
467 |
|
|
Nutrition Composition of Foods |
467 |
|
|
Food Sources of Potassium |
467 |
|
|
Food Sources of Phosphorus |
468 |
|
|
Protein Quality in Foods |
468 |
|
|
Oxalates in Food |
470 |
|
|
Vitamin Recommendations and Supplementation in CKD |
470 |
|
|
Assessment Tools |
470 |
|
|
Internet Sites |
476 |
|
|
Tablet and Smartphone Applications |
476 |
|
|
Summary |
478 |
|
|
References |
478 |
|
|
Index |
480 |
|